Adicet Bio, Inc. (ACET)
After hours:
| Previous close | 1.4800 |
| Open | 1.5000 |
| Bid | 1.4400 x 400 |
| Ask | 1.4900 x 200 |
| Day's range | 1.4200 - 1.5260 |
| 52-week range | 1.1000 - 5.8100 |
| Volume | |
| Avg. volume | 1,259,082 |
| Market cap | 119.152M |
| Beta (5Y monthly) | 1.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9400 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.00 |
Business WireAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON, May 31, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on May 31, 2024.
Business WireAdicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference
REDWOOD CITY, Calif. & BOSTON, May 29, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 5-6, 2024 in New York.
Business WireAdicet Reports First Quarter 2024 Financial Results and Provides Business Updates
REDWOOD CITY, Calif. & BOSTON, May 14, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2024.
